Synopsis
Heterogeneity in breast cancer is
related to aggressiveness and poor prognosis. In this study, we evaluated if qualitative
visual evaluation and quantitative assessment with histogram analysis of tumor
heterogeneity on diffusion weighted imaging (DWI) could be used to predict
molecular subtype in invasive breast cancer. We retrospectively
evaluated 91 patients with invasive ductal carcinoma. Two radiologists
classified the imaging appearance of tumors on DWI according to heterogeneity. The
lesions were also evaluated with histogram analysis on apparent diffusion
coefficient maps. There was no statistically significant difference on
heterogeneity among molecular subtypes on visual evaluation or histogram
analysis.
Introduction
The
heterogeneity in breast cancer is related to aggressiveness and poor prognosis (1). Tumor aggressiveness can also be assessed
based on gene-expression profiling, which establishes a classification of
breast tumors in four different molecular subtypes: luminal A; luminal B;
HER2-enriched; and triple negative/basal-like (2-4).
More aggressive tumor subtypes, like Her2-enriched and triple negative, have a
propensity for metastatic disease and thus require effective treatment (5-7).
Diffusion-weighted
imaging (DWI) measures the random motion of water molecules with diffusivity
providing a surrogate marker for tissue cellularity, microstructure and tumor
heterogeneity (8, 9).
The diffusivity can be quantified by calculation of the apparent diffusion
coefficient (ADC) and previous studies show that ADC values are associated with
tumor aggressiveness and prognosis (10-13).
Tumor heterogeneity on DWI can be qualitatively evaluated with visual
assessment, yet it is subjective and may be prone to inter- and intra-observer
variability. Histogram analysis, a method with which one can quantitatively
evaluate the distribution of different ADC values within a lesion, may be used
to characterize tumor heterogeneity and thereby identify more aggressive
molecular breast cancer subtypes.
In
this context, the aim of this study was to investigate if quantitative
objective histogram analysis or qualitatively visual assessment of tumor
heterogeneity on DWI could differentiate molecular subtypes of invasive breast
cancers.Material and Methods
In
this Health Insurance Portability and Accountability Act compliant and
Institutional Review Board approved study, we retrospectively selected
consecutive patients from January 2011 to January 2013 with invasive ductal
carcinoma of the breast who underwent MRI with DWI with ADC mapping at our
institution. The exclusion criteria were 1) lesion with less than 1 cm, 2)
previous treatment for breast cancer, 3) pathology report unavailable, and 4)
poor DWI image quality. A total of 91 patients were included in the study.
Two
radiologists specializing in breast imaging independently evaluated the MRI
studies. The breast tumors were first visualized on contrast-enhanced
T1-weighted images and then on DWI and classified according to the degree of
heterogeneity. Tumor heterogeneity on DWI was graded on a scale from one to
four, being 1=homogeneous, 2=mildly heterogeneous, 3=moderately heterogeneous,
and 4=highly heterogeneous. In patients with more than 1 lesion, only the
largest was evaluated. A region of interest was drawn on ADC maps on the slice
with the largest diameter covering the whole lesion, taking care to avoid biopsy
markers. Histogram analyses was then
performed and mean, standard deviation, median, 25% quartile, 75% quartile, 10%
quartile, 90% quartile, kurtosis and skewness of ADC values were calculated. Molecular
breast cancer subtypes were derived via IHC surrogates. Tumors were classified
as luminal A if either ER or PR was positive and HER2 was negative, Luminal B if
either ER or PR was positive and HER2 positive, HER2-enriched if ER and PR were
negative and HER2 positive and basal-like if ER, PR and HER2 were negative. Mann-Whitney
statistical tests were used to compare results among different molecular
subtypes.Results
The ADC values from HER2-enriched tumors were greater than
other subtypes, and were statistically significant for ADC 75% and ADC 90%
quartiles when compared to luminal tumors (p=0.0180 and 0.0197, respectively)
and when compared to triple negative/basal-like (p=0.0429 for both). The
histogram analysis quantitative markers of heterogeneity, which included
standard deviation, kurtosis and skewness, were not statistically significantly
different among molecular tumor subtypes (Figure 1).
Qualitative visual assessment of tumor heterogeneity on DWI independently
performed by two radiologists demonstrated a greater heterogeneity of more
aggressive molecular subtypes, i.e. HER2-enriched and triple negative/basal-like
tumors compared to luminal cancers. However, there was also no statistically
significant difference among molecular subtypes with respect to heterogeneity classification
(Figures 2 and 3).Discussion
Previous studies have investigated histogram analysis of
breast lesions for differentiation of benign from malignant lesions according to
heterogeneity (14). Whereas there are differences in heterogeneity
between benign and malignant lesions, gradations of tumor heterogeneity within
molecular subtypes on DWI have not yet been investigated. Our results are in
agreement with a previous study by Park et al. (15) which did not show a significant
difference on kurtosis and skewness between less aggressive ductal carcinoma in
situ and invasive carcinoma. However, with the advent of high-throughput
methods to extract multiple imaging parameters, a more sophisticated assessment
of tumor heterogeneity through radiomics analysis of other functional MRI
parameters might be possible and further studies are warranted.Conclusion
In conclusion, neither quantitative objective histogram
analysis nor qualitatively visual assessment of tumor heterogeneity on DWI can
differentiate molecular subtypes of invasive breast cancers. Acknowledgements
No acknowledgement found.References
1. Suo
S, Cheng F, Cao M, Kang J, Wang M, Hua J, et al. Multiparametric
diffusion-weighted imaging in breast lesions: Association with pathologic
diagnosis and prognostic factors. Journal of magnetic resonance imaging : JMRI.
2017;46(3):740-50.
2. Mazurowski MA, Zhang J, Grimm LJ,
Yoon SC, Silber JI. Radiogenomic analysis of breast cancer: luminal B molecular
subtype is associated with enhancement dynamics at MR imaging. Radiology.
2014;273(2):365-72.
3. Huber KE, Carey LA, Wazer DE. Breast
cancer molecular subtypes in patients with locally advanced disease: impact on
prognosis, patterns of recurrence, and response to therapy. Semin Radiat Oncol.
2009;19(4):204-10.
4. Lam SW, Jimenez CR, Boven E. Breast
cancer classification by proteomic technologies: current state of knowledge.
Cancer treatment reviews. 2014;40(1):129-38.
5. Ko ES, Kim JH, Lim Y, Han BK, Cho
EY, Nam SJ. Assessment of Invasive Breast Cancer Heterogeneity Using
Whole-Tumor Magnetic Resonance Imaging Texture Analysis: Correlations With
Detailed Pathological Findings. Medicine (Baltimore). 2016;95(3):e2453.
6. Fan M, He T, Zhang P, Zhang J, Li L.
Heterogeneity of Diffusion-Weighted Imaging in Tumours and the Surrounding
Stroma for Prediction of Ki-67 Proliferation Status in Breast Cancer. Sci Rep.
2017;7(1):2875.
7. Li X, Kang H, Arlinghaus LR,
Abramson RG, Chakravarthy AB, Abramson VG, et al. Analyzing Spatial
Heterogeneity in DCE- and DW-MRI Parametric Maps to Optimize Prediction of
Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer. Transl Oncol.
2014;7(1):14-22.
8. Hassanzadeh E, Glazer DI, Dunne RM,
Fennessy FM, Harisinghani MG, Tempany CM. Prostate imaging reporting and data
system version 2 (PI-RADS v2): a pictorial review. Abdominal radiology (New
York). 2017;42(1):278-89.
9. Partridge SC, McDonald ES. Diffusion
weighted magnetic resonance imaging of the breast: protocol optimization,
interpretation, and clinical applications. Magn Reson Imaging Clin N Am.
2013;21(3):601-24.
10. Durando M, Gennaro L, Cho GY, Giri DD,
Gnanasigamani MM, Patil S, et al. Quantitative apparent diffusion coefficient
measurement obtained by 3.0Tesla MRI as a potential noninvasive marker of tumor
aggressiveness in breast cancer. European journal of radiology.
2016;85(9):1651-8.
11. Kim SH, Cha ES, Kim HS, Kang BJ, Choi
JJ, Jung JH, et al. Diffusion-weighted imaging of breast cancer: correlation of
the apparent diffusion coefficient value with prognostic factors. Journal of
magnetic resonance imaging : JMRI. 2009;30(3):615-20.
12. Park SH, Choi HY, Hahn SY.
Correlations between apparent diffusion coefficient values of invasive ductal
carcinoma and pathologic factors on diffusion-weighted MRI at 3.0 Tesla.
Journal of magnetic resonance imaging : JMRI. 2015;41(1):175-82.
13. Costantini M, Belli P, Rinaldi P, Bufi
E, Giardina G, Franceschini G, et al. Diffusion-weighted imaging in breast
cancer: relationship between apparent diffusion coefficient and tumour
aggressiveness. Clinical radiology. 2010;65(12):1005-12.
14. Nogueira L, Brandao S, Matos E, Nunes
RG, Loureiro J, Ramos I, et al. Application of the diffusion kurtosis model for
the study of breast lesions. European radiology. 2014;24(6):1197-203.
15. Park
GE, Kim SH, Kim EJ, Kang BJ, Park MS. Histogram analysis of volume-based
apparent diffusion coefficient in breast cancer. Acta Radiol.
2017;58(11):1294-302.